J Kargl1, L Andersen1, C Hasenöhrl1, D Feuersinger1, A Stančić1, A Fauland2, C Magnes2, A El-Heliebi3,4, S Lax5, S Uranitsch6, J Haybaeck7, A Heinemann1, R Schicho1. 1. Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria. 2. HEALTH - Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft m.b.H., Graz, Austria. 3. Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria. 4. Biobank Graz, Medical University of Graz, Graz, Austria. 5. Department of Pathology, General Hospital Graz West, Graz, Austria. 6. Department of Surgery, St John of God Hospital Graz, Graz, Austria. 7. Institute of Pathology, Medical University of Graz, Graz, Austria.
Abstract
BACKGROUND AND PURPOSE: Tumour cell migration and adhesion constitute essential features of metastasis. G-protein coupled receptor 55 (GPR55), a lysophospholipid receptor, has been shown to play an important role in carcinogenesis. Here, we investigated the involvement of GPR55 in migration and metastasis of colon cancer cells. EXPERIMENTAL APPROACH: Adhesion and migration assays using the highly metastatic colon cancer cell line HCT116 and an in vivo assay of liver metastasis were performed. The GPR55 antagonist CID16020046, cannabidiol, a putative GPR55 antagonist and GPR55 siRNA were used to block GPR55 activity in HCT116 colon cancer cells. KEY RESULTS: HCT116 cells showed a significant decrease in adhesion to endothelial cells and in migration after blockade with CID16020046 or cannabidiol. The inhibitory effects of CID16020046 or cannabidiol were averted by GPR55 siRNA knock down in cancer cells. The integrity of endothelial cell monolayers was increased after pretreatment of HCT116 cells with the antagonists or after GPR55 siRNA knockdown while pretreatment with lysophosphatidylinositol (LPI), the endogenous ligand of GPR55, decreased integrity of the monolayers. LPI also induced migration in GPR55 overexpressing HCT116 cells that was blocked by GPR55 antagonists. In a mouse model of metastasis, the arrest of HCT116 cancer cells in the liver was reduced after treatment with CID16020046 or cannabidiol. Increased levels of LPI (18:0) were found in colon cancer patients when compared with healthy individuals. CONCLUSIONS AND IMPLICATIONS: GPR55 is involved in the migratory behaviour of colon carcinoma cells and may serve as a pharmacological target for the prevention of metastasis.
BACKGROUND AND PURPOSE: Tumour cell migration and adhesion constitute essential features of metastasis. G-protein coupled receptor 55 (GPR55), a lysophospholipid receptor, has been shown to play an important role in carcinogenesis. Here, we investigated the involvement of GPR55 in migration and metastasis of colon cancer cells. EXPERIMENTAL APPROACH: Adhesion and migration assays using the highly metastatic colon cancer cell line HCT116 and an in vivo assay of liver metastasis were performed. The GPR55 antagonist CID16020046, cannabidiol, a putative GPR55 antagonist and GPR55 siRNA were used to block GPR55 activity in HCT116 colon cancer cells. KEY RESULTS: HCT116 cells showed a significant decrease in adhesion to endothelial cells and in migration after blockade with CID16020046 or cannabidiol. The inhibitory effects of CID16020046 or cannabidiol were averted by GPR55 siRNA knock down in cancer cells. The integrity of endothelial cell monolayers was increased after pretreatment of HCT116 cells with the antagonists or after GPR55 siRNA knockdown while pretreatment with lysophosphatidylinositol (LPI), the endogenous ligand of GPR55, decreased integrity of the monolayers. LPI also induced migration in GPR55 overexpressing HCT116 cells that was blocked by GPR55 antagonists. In a mouse model of metastasis, the arrest of HCT116 cancer cells in the liver was reduced after treatment with CID16020046 or cannabidiol. Increased levels of LPI (18:0) were found in colon cancer patients when compared with healthy individuals. CONCLUSIONS AND IMPLICATIONS: GPR55 is involved in the migratory behaviour of colon carcinoma cells and may serve as a pharmacological target for the prevention of metastasis.
Authors: E Ryberg; N Larsson; S Sjögren; S Hjorth; N-O Hermansson; J Leonova; T Elebring; K Nilsson; T Drmota; P J Greasley Journal: Br J Pharmacol Date: 2007-09-17 Impact factor: 8.739
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Evangelia Kotsikorou; Haleli Sharir; Derek M Shore; Dow P Hurst; Diane L Lynch; Karla E Madrigal; Susanne Heynen-Genel; Loribelle B Milan; Thomas D Y Chung; Herbert H Seltzman; Yushi Bai; Marc G Caron; Larry S Barak; Mitchell P Croatt; Mary E Abood; Patricia H Reggio Journal: Biochemistry Date: 2013-12-17 Impact factor: 3.162
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: R Ferro; A Adamska; R Lattanzio; I Mavrommati; C E Edling; S A Arifin; C A Fyffe; G Sala; L Sacchetto; G Chiorino; V De Laurenzi; M Piantelli; O J Sansom; T Maffucci; M Falasca Journal: Oncogene Date: 2018-07-30 Impact factor: 9.867
Authors: Solomiia Korchynska; Mirjam I Lutz; Erzsébet Borók; Johannes Pammer; Valentina Cinquina; Nataliya Fedirko; Andrew J Irving; Ken Mackie; Tibor Harkany; Erik Keimpema Journal: JCI Insight Date: 2019-02-21
Authors: Luciana M Leo; Boluwatife Familusi; Michelle Hoang; Raymond Smith; Kristen Lindenau; Kevin T Sporici; Eugen Brailoiu; Mary E Abood; G Cristina Brailoiu Journal: Neuroscience Date: 2019-07-04 Impact factor: 3.590
Authors: Carina Hasenoehrl; David Feuersinger; Eva M Sturm; Thomas Bärnthaler; Ellen Heitzer; Ricarda Graf; Magdalena Grill; Martin Pichler; Stephan Beck; Lee Butcher; Dominique Thomas; Nerea Ferreirós; Rufina Schuligoi; Caroline Schweiger; Johannes Haybaeck; Rudolf Schicho Journal: Int J Cancer Date: 2017-09-21 Impact factor: 7.396